Pharmesis International 

S$0.35
0
+S$0+0% Friday 01:00

統計

當日最高
0.35
當日最低
0.35
52週高點
0.61
52週低點
0.2
成交量
-
平均成交量
-
市值
11.25M
本益比
-
股息殖利率
-
股息
-

股息

0%股息殖利率
Sep 25
S$0.01
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

27Feb預期
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
-0.07
-0.04
-0.01
0.02
預期EPS
不適用
實際EPS
-0.0682

財務

-8.73%利潤率
未盈利
2020
2021
2022
2023
2024
2025
20.92M營收
-1.83M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 BFK.SG 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company provides prescribed products and over-the-counter drugs.It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.
Show more...
執行長
Mr. Xuedan Wu
國家
新加坡
ISIN
SG1BH6000003

上市

0 Comments

分享你的想法

FAQ

Pharmesis International 今天的股價是多少?
BFK.SG 目前價格為 S$0.35 SGD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Pharmesis International 股價表現。
Pharmesis International 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Pharmesis International 的股票以代號 BFK.SG 進行交易。
Pharmesis International 的市值是多少?
今天 Pharmesis International 的市值為 11.25M
Pharmesis International 上一季度的財報如何?
BFK.SG 上一季度的財報為每股 -0.07 SGD,預估為 不適用 SGD,帶來 不適用 的驚喜。下一季度的預估財報為每股 不適用 SGD。
Pharmesis International 去年的營收是多少?
Pharmesis International 去年的營收為 20.92MSGD。
Pharmesis International 去年的淨利是多少?
BFK.SG 去年的淨收益為 -1.83MSGD。
Pharmesis International 會發放股息嗎?
是的,BFK.SG 的股息每 zh-tw 發放一次。每股最新股息為 0.01 SGD。截至今日,股息殖利率(FWD)% 為 0%。
Pharmesis International 位於哪個產業?
Pharmesis International從事於Health & Wellness產業。
Pharmesis International 何時完成拆股?
Pharmesis International 上次拆股發生於 August 27, 2015,比例為 1:10。
Pharmesis International 的總部在哪裡?
Pharmesis International 的總部位於 新加坡 的 Singapore。